Alignment with FDA on CMC and device plans for Phase 3Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials Further strengthening of US and EU mebufotenin patent estatePhase 2a results in postpartum
Issued on behalf of Helus Pharma (NASDAQ:HELP) (Cboe CA: HELP)NEW YORK and TORONTO, July 21, 2026 /CNW/ -- USA News Group - News Commentary - Depression remains one of the most stubborn problems in modern medicine, and
Issued on behalf of Helus Pharma™Eli Lilly's agreement to acquire AtaiBeckley for up to $3.8 billion hands psychedelic medicine its first large-cap validation, and it lands on a late-stage cohort already carrying
NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients relied on
Issued on behalf of Helus Pharma™Helus Pharma™ (NASDAQ:HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., says its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major depressive disorder
DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance of two oral
Phase 2b results in TRD published in JAMA PsychiatryGH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRDGH001-HV-109 US IND-opening study enrolment completedCash,
DUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in
DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in
Phase 2b results for GH001 in TRD now published and peer-reviewed in JAMA Psychiatry New peer-reviewed article in forthcoming issue of Psychopharmacology Bulletin demonstrates that GH001 efficacy is independent of prior
Issued on behalf of Cybin D/B/A Helus PharmaUSANewsGroup.com News CommentaryVANCOUVER, BC, March 9, 2026 /CNW/ -- The central nervous system therapeutics sector is approaching a commercial inflection point as multiple
Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congressesGH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCash, cash equivalents and
Issued on behalf of Helus PharmaVANCOUVER, BC, Feb. 27, 2026 /CNW/ -- Equity-Insider.com News Commentary -- Psychedelic compounds are edging closer to regulatory approval as pivotal trials in treatment-resistant
GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCompany to seek FDA alignment on global Phase 3 program replicating Phase 2b designPhase 3 initiation targeted for 2026 DUBLIN, Jan.
DUBLIN, Jan. 02, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in
